Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$1.98−0.18 (-8.33%)
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
Aligos Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Aligos Therapeutics's total assets was $47.19M at Sep 30, 2026. For fiscal 2025 it was $88.53M, up 26.3% from the year before. The highest annual figure on record is $265.30M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.53M | +26.3% |
| FY2024 | Dec 31, 2024 | $70.09M | -53.7% |
| FY2023 | Dec 31, 2023 | $151.53M | +3.3% |
| FY2022 | Dec 31, 2022 | $146.69M | -37.7% |
| FY2021 | Dec 31, 2021 | $235.37M | -11.3% |
| FY2020 | Dec 31, 2020 | $265.30M | +81.1% |
| FY2019 | Dec 31, 2019 | $146.52M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.19M | -57.0% |
| Q2 FY2026 | Jun 30, 2026 | $66.33M | -50.8% |
| Q1 FY2026 | Mar 31, 2026 | $64.56M | -57.2% |
| Q4 FY2025 | Dec 31, 2025 | $88.53M | +26.3% |
| Q3 FY2025 | Sep 30, 2025 | $109.76M | +24.1% |
| Q2 FY2025 | Jun 30, 2025 | $134.71M | +23.8% |
| Q1 FY2025 | Mar 31, 2025 | $150.70M | +17.8% |
| Q4 FY2024 | Dec 31, 2024 | $70.09M | -53.7% |
| Q3 FY2024 | Sep 30, 2024 | $88.43M | +3.0% |
| Q2 FY2024 | Jun 30, 2024 | $108.81M | +2.5% |
| Q1 FY2024 | Mar 31, 2024 | $127.90M | +5.1% |
| Q4 FY2023 | Dec 31, 2023 | $151.53M | +3.3% |
| Q3 FY2023 | Sep 30, 2023 | $85.85M | -47.7% |
| Q2 FY2023 | Jun 30, 2023 | $106.13M | -41.9% |
| Q1 FY2023 | Mar 31, 2023 | $121.74M | -42.2% |
| Q4 FY2022 | Dec 31, 2022 | $146.69M | -37.7% |
| Q3 FY2022 | Sep 30, 2022 | $164.07M | -37.6% |
| Q2 FY2022 | Jun 30, 2022 | $182.52M | -13.9% |
| Q1 FY2022 | Mar 31, 2022 | $210.47M | -10.3% |
| Q4 FY2021 | Dec 31, 2021 | $235.37M | -11.3% |
| Q3 FY2021 | Sep 30, 2021 | $263.07M | +185.4% |
| Q2 FY2021 | Jun 30, 2021 | $211.88M | +44.6% |
| Q1 FY2021 | Mar 31, 2021 | $234.54M | – |
| Q4 FY2020 | Dec 31, 2020 | $265.30M | – |
| Q3 FY2020 | Sep 30, 2020 | $92.18M | – |
| Q4 FY2019 | Dec 31, 2019 | $146.52M | – |
See a number that looks wrong?